Medical Information

As a gamma secretase inhibitor, attention should be paid to the three major risks of ovarian toxicity, diarrhea, and skin adverse reactions when using Ogsiweio. The following systematically elaborates on relevant precautions from three dimensions: monitoring management, hierarchical processing, and preventive measures.

1. Ovarian toxicity management

(1) Fertility assessment: Prior to treatment, AMH testing and ovarian reserve function assessment are required. Women of childbearing age are advised to freeze their eggs or embryos.

(2) Menstrual monitoring: During the treatment period, record monthly changes in the menstrual cycle. If amenorrhea occurs for more than 3 months, immediate hormone level testing is required.

(3) Alternative therapy: When premature ovarian failure occurs, hormone replacement therapy should be initiated and referred to the reproductive endocrinology department.

2. Diarrhea Management Standards

(1) Graded management: Grade 1 diarrhea (with an increase of less than 4 bowel movements per day) can be treated by adjusting diet and using loperamide; Level 2 (increase 4-6 times) requires a 25% reduction; Medication should be suspended for levels 3 and above.

(2) Electrolyte monitoring: Blood potassium, sodium, and magnesium levels are measured every 48 hours in patients with moderate to severe diarrhea to prevent hypokalemic arrhythmia.

(3) Mucosal repair: It is recommended to use montmorillonite powder combined with probiotics to maintain intestinal microbiota balance.

3. Skin adverse reactions

(1) Grading of rash: Grade 1 (covering<10% of body surface area) Local use of glucocorticoids; Grade 2 (10-30%) oral antihistamines; Level 3 requires hospitalization treatment.

(2) Stevens Johnson syndrome warning: permanent discontinuation of medication when mucosal erosion or epidermal peeling>10% of body surface area occurs.

(3) Photoprotection: During treatment, use SPF50+sunscreen to avoid direct sunlight.

4. Joint monitoring requirements

(1) Baseline examination: A comprehensive assessment of gynecological ultrasound, thyroid function, and dermatological consultation should be completed before treatment.

(2) Periodic monitoring: FSH/LH levels are measured on the first day of each treatment cycle, and skin toxicity scores are performed every two cycles.

(3) Long term follow-up: Continue monitoring ovarian function for at least 12 months after discontinuation of medication, and use contraception for women of childbearing age for 6 months after discontinuation of medication.